Physician profile
Karan Shah
NPI 1477865582
$14,018.20
in general payments reported to CMS, 2019-2025
38 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $2,548 · 2021: $208 · 2022: $3,401 · 2023: $2,976 · 2024: $3,640 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Travel and Lodging: $1,881 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Education: $845 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.73 |
| Travel and Lodging | $1,880.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Education | $845.09 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $5,853.15 | 2021-2024 | Varian Treatment, Aria Radiation Therapy Management Software, Varian Ethos Treatment Planning |
| Carl Zeiss Meditec, INC. | $2,291.18 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $1,904.22 | 2021-2024 | Intrabeam, Iort |
| Astrazeneca Pharmaceuticals LP | $723.46 | 2019-2024 | Imfinzi, Enhertu |
| Ge Healthcare | $664.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $378.52 | 2019-2025 | |
| Astellas Pharma US INC | $313.65 | 2023-2024 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $228.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $209.99 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $141.84 | 2019-2024 | Verzenio, Retevmo |
| Springworks Therapeutics, INC. | $127.27 | 2024 | Ogsiveo |
| Qol Medical, LLC | $124.25 | 2023 | Sucraid |
| Boston Scientific Corporation | $122.40 | 2019-2025 | Spaceoar Vue System - 10ml |
| Reflexion Medical, INC. | $84.56 | 2022-2024 | Reflexion Medical Radiotherapy System |
| Janssen Pharmaceuticals, INC | $76.22 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.